IL6R and neoplasm: At the endpoint (week 7), upon sequential PD-L1 and IL-6R immunotherapy, splenic lymphocytes of the shMCT-1 tumor-bearing mice increased more CD4(+) helper T cells and CD19(+) B cells (Figure 5M) but unchanged CD8(+) CTLs and NK cells (Figure S6H) when compared with those bearing scramble tumors and treated by isotype IgG.